Related Experiment Videos
Childhood acute lymphocytic leukemia: study VIII.
Cancer
|November 1, 1978
Summary
This study on childhood acute lymphoblastic leukemia (ALL) found that adding more drugs to chemotherapy increased toxicity without improving remission rates. Intensive early therapy also did not prolong remission in high-risk patients.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Pharmacology
Background:
- Childhood acute lymphoblastic leukemia (ALL) requires effective and safe treatment strategies.
- Optimizing remission duration and minimizing toxicity are key goals in ALL therapy.
- Identifying prognostic factors for poor outcomes is crucial for treatment stratification.
Purpose of the Study:
- To evaluate the efficacy and toxicity of one-, two-, three-, and four-drug chemotherapy regimens in maintaining remission in pediatric ALL.
- To determine if intensified early therapy improves remission duration in ALL patients with poor prognostic features.
Main Methods:
- A controlled study involving 282 children with ALL.
- Induction of remission using prednisone, vincristine, and asparaginase.
- Randomization of patients to four continuation chemotherapy arms: methotrexate alone, methotrexate plus mercaptopurine, methotrexate plus mercaptopurine plus cyclophosphamide, or methotrexate plus mercaptopurine plus cyclophosphamide plus arabinosyl cytosine.
- Specific treatments for CNS leukemia and anterior mediastinal enlargement.
- Use of daunorubicin and prednisone for non-responders.
Main Results:
- 95% of patients achieved complete remission, and 85% were randomized to continuation therapy.
- Methotrexate monotherapy was associated with a high relapse rate (14/20) and significant leukoencephalopathy (9/20).
- Multi-drug regimens (Groups 2, 3, 4) showed equivalent efficacy to methotrexate alone but without the observed leukoencephalopathy.
- Addition of cyclophosphamide and arabinosyl cytosine increased toxicity and complications without a clear survival benefit.
- Intensified early therapy in 40 high-risk patients did not prolong remission.
Conclusions:
- For pediatric ALL, multi-drug chemotherapy regimens (methotrexate, mercaptopurine, cyclophosphamide, arabinosyl cytosine) did not demonstrate superior efficacy over less complex regimens.
- Increased drug combinations led to higher toxicity and complications without improving leukemocidal effects.
- Intensified early treatment strategies in this study did not improve remission duration for patients with poor prognostic indicators.